Glenmark Pharmaceuticals Limited · NSE:GLENMARK

Glenmark Pharmaceuticals — Q2 FY26 Earnings Presentation

18 slides from Glenmark Pharmaceuticals's earnings presentation, Nov 14, 2025

  1. Slide 1: Exchange filing cover letter

    November 14, 2025 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 532296

  2. Slide 2: Investor Presentation: Q2 FY26

    Investor Presentation: Q2 FY26 14 November 2025

  3. Slide 3: Disclaimer

    Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen

  4. Slide 4: IGI's ISB 2001 partnership with AbbVie: A landmark deal

    IGI’s ISB 2001 partnership with AbbVie: A landmark deal Commercials Grant of Rights • Total Deal Value: US$1.925 billion • AbbVie – exclusive rights to globally develop, o Upfront Payment: US$700 million manufacture, and commercialize across North Deal Terms o Milestones (Development, Regulatory, Am

  5. Slide 5: One-time impact on India business

    One-time impact on India business Glenmark has a unique, legacy 3-tiered distribution system in India, unlike peer companies Increasing uncertainties within the distribution channel related to the implementation of GST regime change post its announcement on August 15, 2025 During Q2 FY26, primary sa

  6. Slide 6: Driving operational excellence for sustainable value creation

    Driving operational excellence for sustainable value creation Objective: To enhance overall operational performance and constantly strive to have best-in-class return ratios across the pharmaceutical industry Key changes implemented in provisioning norms / standard operating practices: These initiat

  7. Slide 7: Q2 FY26 Summary

    Q2 FY26 Summary “Q2 FY26 reflects the steady progress we are making in strengthening Glenmark’s scientific and strategic foundation. The AbbVie partnership for ISB Consolidated • Consolidated Revenue of Rs. 60,469 Mn 2001, along with the income recognised this quarter, is a significant validation Re

  8. Slide 8: Consolidated Revenue – Q2 FY26

    Consolidated Revenue – Q2 FY26 Second Quarter ended September 30 First Quarter ended June 30 YoY Growth QoQ Growth Rs Mn FY 2025-26 FY 2024-25 FY 2025-26 (%) (%) India 1,650 12,817 -87.1% 12,399 -86.7% North America 44,656 7,405 503.0% 7,780 474.0% Europe 7,460 6,874 8.5% 6,678 11.7% 1 Emerging Mark

  9. Slide 9: Q2 FY26 P&L and H2 FY26 Guidance

    Q2 FY26 P&L and H2 FY26 Guidance Revenue Estimated amount in INR million Explanation Business revenue 23,769 GST regime change impact on India business IGI revenue of US$525 million 45,000 All one-time charges related to LCDF impairment and expenditures related to facility closure, including regulat

  10. Slide 10: India

    India Revenue (Rs. million) YoY: -87.1% Ranked 2nd in Dermatology, Strong uptake of QoQ: -86.7% 3rd in Respiratory and 4th TEVIMBRA® and 12,817 12,399 in the Cardiac segment# BRUKINSA® post Q1 launch Key Highlights 1,650  Impact of GST regime change on unique, 3-tiered distribution model led to one

  11. Slide 11: North America

    North America Revenue (Rs. million) YoY: 503% 10 injectable products Leveraging strong QoQ: 474% launched including capabilities in Injectables Micafungin and Eribulin and Respiratory 44,656 Key Highlights 7,405 7,780  Net of the out-licensing income for the ISB 2001 deal, the core business YoY gro

  12. Slide 12: Europe

    Europe Revenue (Rs. million) YoY: 8.5% WINLEVI® launched in the Robust uptick in new QoQ: 11.7% UK; received positive product launches 7,460 opinion from EMA 6,874 6,678 Key Highlights  Continued outperformance in all Central and Eastern European markets Q2 FY26 Q2 FY25 Q1 FY26  Western European b

  13. Slide 13: Emerging Markets (EM)

    Emerging Markets (EM)1 Revenue (Rs. million) Reported growth impacted YoY: -6.5% due to geopolitical RYALTRIS® continuing to QoQ: 15.1% uncertainties in certain scale up across markets 7,041 markets 6,585 5,721 Key Highlights  Russia: Secondary sales growth of 8.1%; RYALTRIS® sustained its momentum

  14. Slide 14: Global Innovative / Specialty Portfolio

    Global Innovative / Specialty Portfolio RYALTRIS®  As of September 2025, marketing applications submitted in more than 90 countries across the world; product commercialized in 49 markets.  Expected to be launched in 10-12 additional markets over the next few quarters  As per IQVIA September 2025

  15. Slide 15: Global Innovative / Specialty Portfolio

    Global Innovative / Specialty Portfolio QiNHAYO (ENVAFOLIMAB)  Filed QiNHAYO Marketing Authorization Applications in 14 markets till date; the first commercial launch is expected in FY26.  Received authorization from the regulatory authority in Kenya for supply of Envafolimab via early access prog

  16. Slide 16: Diversity Of Immune Cell Engagement And Indications Across Hematologic And Solid Tumours

    Diversity Of Immune Cell Engagement And Indications Across Hematologic And Solid Tumours GLOBAL ASSET DESCRIPTION INDICATION DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 RIGHTS CD38 x BCMA x CD3 Multiple ISB 2001 TREAT trispecific T-Cell Engager Myeloma Hidradenitis ISB 880 / ALM27134 IL-1RAP anta

  17. Slide 17: IGI - Key updates

    IGI - Key updates  ISB 2001/ABBV-2001 o IGI is currently executing a Phase 1 study (TRIgnite-1) in Australia, United States and several European countries. The study continued to Dose Expansion in April 2025 and is continuing to rapidly enroll patients. o IGI received an upfront payment of US$700 m

  18. Slide 18: Thank You

    G Glenmark Thank You

Glenmark Pharmaceuticals — Q2 FY26 Earnings Presentation on 6ix